

## POSTER PRESENTER ABSTRACT INDEX

First Name	LAST NAME	Poster #	Abstract Title
Teshale	ARAYA	P1	Generation and Evaluation of an African Swine Fever Virus Mutant with Deletion of the CD2v and UK Genes
Angela	GWAKISA	P2	A Phase III randomized controlled multi-centre trial to evaluate the efficacy of the R21/Matrix-M vaccine in African children against clinical malaria
Gyunghee	JO	P3	Structural basis of broad protection against influenza virus by a human antibody targeting the neuraminidase active site through a recurring motif in CDR-H3
Aina-ekisha	Kahatano	P4	A randomised, controlled, double-blind, parallel group, single center Phase Ib trial to assess safety, reactogenicity and immunogenicity of a candidate dual-stage malaria vaccine, SumayaVac-1 (MSP-1 with GLA-SE as adjuvant) in healthy malaria exposed adults of African origin aged 18-45 years
Soojeong	CHANG	P5	Strategy to develop updated COVID-19 vaccines based on Ad5/35 platform for effective response to emerging variants
Mammar	KHAMES	P6	Is the cessation of vaccination of small ruminants with Rev-1 responsible for the highly endemic situation of human brucellosis in Algeria?
Farhana	KHANAM	P7	Evaluation of oral cholera vaccine (Euvichol-Plus) effectiveness against Vibrio cholerae in Bangladesh: An interim analysis
Yana	KUMPANENKO	P8	YF17D-vectored COVID-19 vaccine protects from SARS-CoV-2-induced adverse pregnancy outcomes in a hamster model of COVID-19
Alexander	SAMPSON	P9	Improving humoral immunogenicity of adenoviral vector vaccines by capsid display
Jonas	DELVA	P10	Dose-ranging study of a self-amplifying RNA and LNP-carrier vaccine in mice and pigs
Moshi	SHABANI	P11	Safety of the candidate rabies vaccine ChAdOx2 RabG in adult and pediatric populations from a rabies endemic region: A Phase Ib/II age de-escalation, dose escalation, open-label head-to-head, partially randomized clinical trial
Nontobeko	THEMA	P12	Single dose new generation heartwater vaccine for smallholder farmers
Tomoya	HAYASHI	P13	Nanoparticle mapping and sorting to assess quality and bioactivity of particulate vaccines and viruses
Ah-Ra	KIM	P14	Analysis of Neutralizing Antibody Dynamics According to COVID-19 Vaccination Status: A Comparative Study of vaccine strain and circulating variant
Masaki	MACHIDA	P15	Exploring regional disparities in measles vaccination coverage and influencing factors: an ecological study in Japan, FY 2022
Ebony	GARY	P16	Peripheral co-delivery of plasmid-encoded mucosal chemokine CCL27 enhances mucosal immunity and supports protection from heterologous SARS-CoV-2 and H5N1 influenza challenges in vivo
Jaclynn	MESHANNI	P17	Targeted delivery of immunotherapeutics to the lower regions of the lung: using one-component ionizable Amphiphilic Janus Dendrimers to deliver TGF $\beta$ mRNA to the lung parenchyma.
Tien Duc	NGUYEN	P18	A built-in flagellin adjuvanted ferritin nanocage mucosal vaccine platform induces high-quality protective immune responses against respiratory infections
Dr. Sneha	RAJ	P19	Long term immune responses study of Influenza B derived recombinant trimeric soluble Hemagglutinin (HA) antigen in mice
		P20	Poster Withdrawn
Alexander	COHEN	P21	Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals
Daniel	YARA	P22	Mapping the serological response to Chikungunya infection and vaccination
Cara	Chao	P23	Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV
Zahraa	AL-DELFI	P24	Leveraging non-spike antigens for broad immune protection against SARS-CoV-2 Variants
Charlie	AMOIA	P25	Evaluation of an adjuvanted DNA vaccine for the control of virulent strains of New castle disease virus
Imen	AYOUNI EP LABIDI	P26	Intention to receive COVID-19 and Influenza vaccines during pregnancy: a prospective cross-sectional study among pregnant women attending antenatal care in Cape Town.
Elias	BROECKHOVEN	P27	Efficient HBV immunization using a self-powered microfluidic chip for reconstitution and intradermal delivery of CpG-adjuvanted HBs vaccine
Seo-Hyeon	BAE	P28	Feasibility of Smart LNP Monitoring: Intelligent Screening Technologies for designing ionizable lipid and optimizing LNP
Nicole	CHINEKA	P29	DEVELOPMENT OF A DUAL VACCINE AGAINST BOVINE CORONAVIRUS AND LUMPY SKIN DISEASE VIRUS.
Madison	DAVIS	P30	Cinnamon and Spice as Adjuvants are Nice: Targeting TRP Channels to Boost Mucosal Immunization
Kirti	DAYA	P31	The comparison of plant virus nanoparticles in the presentation of a conserved influenza epitope to develop a universal influenza vaccine candidate in Nicotiana benthamiana
Kawkab	KANJO	P32	High throughput epitopemapping using charge scanning mutagenesis
Lara	KELCHTERMANS	P33	Broad filovirus protection via NK cell activation and neutrophil phagocytosis in mice induced by a YF17D-vectored Sudan virus vaccin
Seongje	CHO	P34	mRNA-based personalized cancer vaccines in colorectal cancer in mouse model: Early vaccination as a strategic treatment
Youngran	CHO	P35	A Quadrivalent mRNA Vaccine Against HSV-2 Showed the Enhanced Immunogenicity and Protection Against Primary and Latent Infections.
Arturo	LIÑAN-TORRES	P36	RATIONAL DESIGN AND EXPERIMENTAL VALIDATION OF VACCINE CANDIDATES AGAINST SARS-CoV-2 BASED ON T-CELL EPITOPES

Huijong	CHOI	P37	Integration of TLR7/8 Agonists in Lipid Nanoparticle Delivery Systems Enhanced Modified mRNA Vaccine Efficacy for Cancer Immunotherapy
Margarette	MARIANO	P38	A Two-Component Cocktail of Engineered E Domain III Nanoparticles Elicits Broadly Neutralizing Antibody Responses against Dengue virus in Mic
Nur Ain	Mohd Asri	P39	Novel Tuberculosis (TB) Oral Vaccine Candidate: Enhancing Mucosal Immunity with Recombinant Secretory IgA (SigA) in Goat Milk
Giang	DANG CHAU	P40	Development of a cross-presentation enhancing flagellin-based adjuvant for cancer vaccines: the Flt3L-FlaB hybrid adjuvant
Ryan	SANTOS	P41	Eliminating the Risk of Antibody-Dependent Enhancement with Multivalent ZIKV DNA Vaccines
Sebastian	TRINITARIO	P42	Novel adenoviral vaccine candidate against a century-old disease: the ongoing search for an efficient immune-mediated control of chagas disease
Abubakar	WOZIRI	P43	Design and In-Silico evaluation of a novel multiepitope-based recombinant DNA Vaccine Candidate against Lassa Hemorrhagic Fever
Dahyeon	HA	P44	Enhanced Sensitivity in Assessing mRNA-LNP Vaccine Reactogenicity Using IL-1ra Knockout Mice
Takuya	HEMMI	P45	Exploring COVID-19 vaccine antigen design guidelines to improve the efficiency of broadly neutralizing antibody induction
Matěj	HLAVÁČ	P46	High-Capacity Adenoviral Vectors as a Novel Platform for Multi-Pathogen Vaccines
Sohee	JO	P47	Dose-Dependent Effects of dsRNA Contamination on mRNA Vaccine Expression and Immunogenicity: Implications for Optimization of mRNA Production and Purification
Yoshino	KAWAGUCHI	P48	Modification of PEG-lipids and phospholipids in mRNA-lipid nanoparticle vaccines reduce adverse reactions with sustained efficacy
Min Xuan	Keh	P49	Detection of Chimeric Secretory IgA: TB Multi-epitopes Protein in Milk samples and Protein purification in Development of Mucosal Vaccine Against Tuberculosis
Seo-Yeon	KIM	P50	Enhanced immunogenicity of hetero-bivalent SARS-CoV-2 mRNA vaccine strategy
Soo Ji	KIM	P51	Systems serology-based comparison of humoral responses induced by liposome or alum adjuvanted SARS-CoV-2 spike protein
Soo-Yeon	LEE	P52	Therapeutic Potential of mRNA-Encoded Human Neutralizing Antibody Against SFTSV Gn
Soo-Yeon	LEE	P53	Comparative Analysis of Expression Dynamics, Immunogenicity, and Safety Profiles for Linear and Circular mRNA Vaccine Platforms
Jung Hyuk	LEE	P54	Dose-Dependent Serological Profiling of AdCLD-CoV19-1 Vaccine in Adults
Jinting	LI	P55	The research and development of a human cytomegalovirus vaccine
Elizabeth	MCFADDEN	P56	Engineering, structure, and immunogenicity of a Crimeanâ€Congo hemorrhagic fever virus pre-fusion heterotrimeric glycoprotein complex
Sung-Sil	MOON	P57	Evaluating Stability, Toxicity, and Immunogenicity of Inactivated Rotavirus Vaccine using a Dissolving Microneedle Patch
Chenyuan	QIN	P58	Attitudes towards vaccination against COVID-19 during pregnancy and its determinants among people of reproductive age
Chengwei	SHAO	P59	Evaluation of Immunogenicity and Safety of the COVID-19 DNA Vaccine INO-4800 in China
DR. PREETI	VISHWAKARMA	P60	Immunogenicity and protective efficacy study of pentameric M2e-based subunit immunogen expressed in mammalian cells
Jing	WANG	P61	High-throughput mutation escape profiling accelerates antibody evaluation and vaccine design
Hui	ZHENG	P62	Immune responses and transcription landscape of adults with the third dose of homologous and heterologous booster vaccines of COVID-19
Zhang	YU	P63	Lyophilized PLGA hollow microcapsules promote broad antibody and T-cell responses by enhancing antigen presentation
Thuy An	PHAM	P64	Mycobacterial fusion protein eliciting anti-tumor activity through NK cells activation
Jae Seung	YANG	P65	Salmonella Typhi Vi-specific serological profiling among children, adolescent, and adults after typhoid vaccination
Seonghyun	LEE	P66	Assessing the Efficacy of Modified Nucleoside mRNA Vaccine in Chronic Inflammation
Ayoung	OH	P67	Impact of Poly(A) Tail Structures on Expression and Immune Responses in mRNA Vaccine Efficacy
Mohd Hatimi	TUKIMAN	P68	Immunogenicity of Recombinant Secretory Immunoglobulin A - Antigen 85B Chimeric Protein in Goat's Milk as a Potential Booster Vaccine against Tuberculosis in BCG-Primed Mice
Jeffrey	Chen	P69	A novel bovine TB vaccine borne unexpectedly out of basic Mycobacterium tuberculosis-complex virulence research
Weixiao	WANG	P70	Preparation and Immunogenicity Study of Novel Hepatitis B Virus-like Particles
Yu	SUN	P71	Activation of Innate Immunity by Aluminum Adjuvant Enhances 2'3'-cGAMP and Decitabine Delivery for Antitumor Therapy
Andani	TSHIITAMUNE	P72	Plant-Produced Recombinant Influenza A Virus Candidate Vaccine Targeting the Conserved M2e Protein and Hemagglutinin Stalk Region
Mihai	AZOITEI	P73	Rational Immunogen Design for a Pan-Betacoronavirus Vaccine
Aleksandr	BARINOV	P74	Preclinical Evaluation of MVdeltaC: An Oncolytic Virus Derived from Measles Schwarz Vaccine for Cancer Therapy
Frank, Chia-Jung	CHANG	P75	Efficacy of a ready-to-use porcine bivalent mycoplasma subunit vaccine against Mycoplasma hyorhinis and Mycoplasma hyopneumoniae challenge
EUNJIN	CHOI	P76	Synergistic Effects of Codon Optimization and Wild-Type UTP for Enhancing mRNA Therapeutic Efficacy
Susanne	EDER-LINGELBACH	P77	Two-year antibody persistence and safety of a single-dose live-attenuated chikungunya virus vaccine (VLA1553) in adults aged 18 years and above

Phanramphoei	FRANTZ	P78	An Improved Measles Virus Vaccine Vector for Rescuing Recombinant Measles Expressing Large and Multiple Heterologous Antigens: Creating a Three-in-One Vaccine
Deborah	FULLER	P79	Multigenic universal influenza DNA vaccine delivered via needle-free gene gun induces broad immunity against diverse influenza viruses in mice and nonhuman primates
Toshiro	HIRAI	P80	Hypertonic intranasal vaccines gain nasal epithelia access to exert strong immunogenicity
Tetsuro	IKEGAMI	P81	Evaluation of Attenuation Phenotype of the Live-Attenuated Rift Valley Fever Candidate Vaccine, RVax-1, in Prewaning and Pregnant C57BL/6 Mice
Ji Hyang	JEON	P82	Innate immune responses against mRNA vaccine promote cellular immunity through IFN- $\gamma$ at the injection site
Sookyung	JEONG	P83	L-pampo™, a TLR2/3 agonist, can be a potent vaccine adjuvant targeting respiratory infectious diseases
Kouji	KOBIYAMA	P84	Immunological and pathological analysis of mpox vaccine, LC16m8
Lakshmi	KRISHNAN	P85	A New Public Facility That Bridges Vaccine Biomanufacturing for Clinical Trials – The National Research Council (NRC) of Canada’s Clinical Trial Material Facility
Hao	LI	P86	A novel subunit vaccine Ag85A-LpqH focusing on humoral immunity provides substantial protection against tuberculosis in mice
Jue	LIU	P87	Coverage and vaccine hesitancy of influenza vaccination among reproductive-age women (18-49 years old) in China
Doan	NGUYEN	P88	SARS-CoV-2 Plasma Cells are Largely Excluded from the Bone Marrow Long-Lived Compartment 33 Months after mRNA Vaccination
Mai	ONAGA	P89	Synergistic activation of STING and TLR9 for cancer immunotherapy
Wenjuan	PENG	P90	Development of Serum-free Medium Based on Deep-learning Artificial Intelligence Platform to Enhance the Production of Influenza Vaccines with MDCK Cells
Venigalla	RAO	P91	Bacteriophage T4 as a Protein-Based, Adjuvant- and Needle-Free, Mucosal Pandemic Vaccine Design Platform
Sang Hwan	SEO	P92	Prime-Boost Immunization of Inactivated Human Adenovirus Type 55 combined with an Adjuvant Enhances Neutralizing Antibody Responses in Mice
Burcu	TEMIZOZ	P93	Combination adjuvants targeting nucleic acid sensors for cancer immunotherapy
Asuka	TOBUSE	P94	K3-SPG-mediated long-term protection against viral infection
Joo sung	WOO	P95	Quantification of polysaccharides in trivalent iNTS-typhoid glycoconjugate vaccine by high-performance anion-exchange chromatography with pulsed amperometric detection
Qingqing	ZHANG	P96	Structure-based antigen design for serogroup B N. meningitidis vaccine
Lee-Jah	Chang	P97	Safety and immunogenicity of a SARS-CoV-2 mRNA virus-like particle vaccine in adults 18 years of age and older in a Phase 1 randomized clinical trial
Jian Hang	LAM	P98	Development of a thermostable, immunogenic ACM Tunable Platform (ATP) for mRNA delivery using amphiphilic block co-polymers
Derrick	Cha	P99	MONTANIDE®, ISA 51 VG: open access adjuvant dedicated to therapeutic vaccines
Fengge	WANG	P100	Cost-Effectiveness Analysis of Hepatitis E Vaccination Strategies for Swine-Related Occupational Workers
Michael	MCCLUSKIE	P101	The Development of Sulfated Lactosyl Archaeol (SLA) Archaeosomes as a Vaccine Adjuvant
Jeffrey	CHEN	P102	Leveraging the genetic diversity of the live TB vaccine M. bovis bacillus Calmette-Guerin (BCG) to identify novel components of the T7SS ESX-1
Yuanqing	LIU	P103	DEVELOPING THE NEXT GENERATION OF THERMAL STABLE mRNA VACCINES AGAINST VIRAL AND BACTERIAL PATHOGENS
SoJung	AN	P104	Development and Preclinical evaluation of Novel Trivalent iNTS/Typhoid Vaccine
SoJung	AN	P105	A proof-of-concept for a bivalent Paratyphoid and Typhoid vaccine development in animals
Corine	KRUISWIJK	P106	Development of a broadly protective Outer Membrane Vesicle based beta coronavirus vaccine
Guilhem	RICHARD	P107	Artificial and Human Intelligences Combined: Removal of Inhibitory Sequences Improves Vaccine Immunogenicity and Efficacy
Jungkuk	HUR	P108	Cancer Vaccine Adjuvant Name Recognition from Clinical Trial Data using Large Language Models
Ravi	Ganapathy	P109	Bioprocess improvement to increase manufacturing yield using a fixed-bed bioreactor
Stefan	SLAMANIG	P110	An intranasal Newcastle disease virus (NDV)-based SARS-CoV-2 Omicron vaccine elicits protective immune responses in mice and hamsters
Mi Young	KIM	P111	Rapid Vaccine Development Projects to prepare for Pandemics in Republic of Korea
Juan	GARCI-A-ARRIAZA	P112	Heterologous prime/boost immunization with Newcastle disease virus and modified vaccinia virus Ankara vectors as an improved and effective strategy against SARS-CoV-2 infection
Juan	GARCI-A-ARRIAZA	P113	Vaccine candidates based on the poxvirus MVA vector expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta, and Omicron BA.1 variants elicit robust humoral and T-cellular immune responses and protect K18-hACE2 mice against SARS-CoV-2 Omicron infection
Bin	WANG	P114	Potent immunogenicity and broad-spectrum protection potential of dissolvable-microneedle array patch-based COVID-19 DNA vaccine candidates

Jayalakshmi	<b>THIRUPPATHI</b>	<b>P115</b>	Thermoresistant flagellin adjuvanted cancer vaccine synergizes with photothermal therapy of breast cancer
Mangala	<b>RAO</b>	<b>P116</b>	ARMY LIPOSOME FORMULATION CONTAINING QS-21 MODULATES PROINFLAMMATORY MILIEU AND INNATE ANTI-VIRAL FACTORS RENDERING HUMAN MONOCYTE-DERIVED MACROPHAGES LESS PERMISSIVE TO HIV-1 INFECTION
David	<b>WEINER</b>	<b>P117</b>	Lipid formulated plasmid DNA drives robust innate immune activation to promote adaptive immunity
Hyun	<b>BYUN</b>	<b>P118</b>	Virus-free Recombinant VLP Vaccine for Polio Virus Eradication
Hyun	<b>BYUN</b>	<b>P119</b>	Bacterially Production of Recombinant Pentamer Scaffolded West Nile Virus Vaccine
Sin Hae	<b>KANG</b>	<b>P120</b>	A Novel Green Technology Platform for Inactivated Vaccines: EGCG (Epigallocatechin-3-gallate)-Inactivated Zika Virus Vaccine
Nikolai	<b>SCHERBAK</b>	<b>P121</b>	Engineering E. coli Nissle 1917 for Enhanced Mucosal Vaccine Development: Stable Expression of HIV-1 MPER in Outer Membrane Protein F and Outer Membrane Vesicles.
Falko	<b>APEL</b>	<b>P122</b>	VFI Adjuvants for Global Health
Jie	<b>DENG</b>	<b>P123</b>	Pandemic Fatigue and Vaccine Hesitancy among People Who Have Recovered from COVID-19 Infection in the Post-Pandemic Era: A Cross-Sectional Study in China
Barbara	<b>FELBER</b>	<b>P124</b>	Transient innate immune responses induced by DNA/LIONâ„¸ vaccine shape long-lasting immunity against different antigens
Jae Won	<b>HAN</b>	<b>P125</b>	RNA as Chaperone (Chaperna) for the Assembly of Virus-like Particles and Nanoparticle Vaccines
Eun-Kyeong	<b>JO</b>	<b>P126</b>	Autophagy as a therapeutic target for innate host defense during mycobacterial infections
Hanul	<b>KANG</b>	<b>P127</b>	Recombinant Pertussis Vaccine as an Alternative to Traditional Acellular Vaccine
Tae Hoon	<b>KIM</b>	<b>P128</b>	Chaperna Assisted Self-Assembly of Foot and Mouth Disease Virus (FMDV) Virus Like Particle (VLPs) Vaccine
Cunbao	<b>LIU</b>	<b>P129</b>	An economical adjuvant without a production limit to induce potent cell-mediated immunity in subunit vaccines
Seo Young	<b>MOON</b>	<b>P130</b>	Phylogenetic and genetic analysis of the Hendra virus and Nipah viurs
Seong Hyun	<b>PARK</b>	<b>P131</b>	â€100 Days Missionâ€ Speedy Delivery of Disease X Vaccines: Chaperna platform based Bacterially Produced Highly Pathogenic Avian Influenza Virus Nanoparticle Vaccine.
Waranyoo	<b>Phoolcharoen</b>	<b>P132</b>	In vitro and in vivo studies of plant-produced Atezolizumab as a potential immunotherapeutic antibody
Yufei	<b>XIA</b>	<b>P133</b>	Engineering Pickering emulsion for the advanced vaccine adjuvant
Jiwon	<b>BAEK</b>	<b>P134</b>	Immunogenicity in Recombinant Protein Vaccine Candidates Targeting Nipah virus
Cristina	<b>GINGERICH</b>	<b>P135</b>	An intranasal parainfluenza virus 5 (PIV5)-based vaccine for Lyme Disease induces protection against multi-strain Borrelia burgdorferi tick challenge in mice
Kaoru	<b>ARAKI</b>	<b>P136</b>	Psychological determinants of HPV vaccine hesitancy among females of catch-up generations in Japan: Internet survey
Zachary	<b>Jones</b>	<b>P137</b>	Development of stabilized Rift Valley Fever Virus immunogens
Michael	<b>SCHOTSAERT</b>	<b>P138</b>	Lung eosinophil recruitment and type 2 host immune responses in vaccinated mice is non-pathological and correlates with protection during influenza infection in mice with infection-permissive or sterilizing immunity.
Seung Yun	<b>Yang</b>	<b>P139</b>	Accurate Transcutaneous Immunization of High-dose Live Vaccines using Multi-coated Microneedle Array Patches
Alexander (Sandy)	<b>Douglas</b>	<b>P140</b>	Novel rabies vaccine offers potential for population wide pre-exposure prophylaxis in rabies endemic areas
Essie	<b>KOMLA</b>	<b>P141</b>	Development of HIV mRNA Lipid Nanoparticles (LNPs) Vaccine Formulation
Seung-Ah	<b>Choe</b>	<b>P142</b>	NVX-CoV2373 Vaccine Exposure During Pregnancy and Risk of Adverse birth outcomes: Korean Nationwide Population Study
WEIPING	<b>ZHANG</b>	<b>P143</b>	A protein-based multivalent cholera vaccine candidate broadly protects against Vibrio cholerae serogroup infections
Heejin	<b>YUN</b>	<b>P144</b>	System Vaccinology Approach Identifies an Early Innate Immune Signature as a Correlated of Humoral and Cell-mediated Immune Responses to the rVSV $\Delta$ GP-LASV-GPC in Phase 1 Clinical Trial
Dah Hyun	<b>Moon</b>	<b>P145</b>	Development of Novel Recombinant Vaccine against Re-emerging Genotype V Japanese Encephalitis Virus
Fumihiko	<b>YASUI</b>	<b>P146</b>	Protective efficacy of a non-proliferative attenuated vaccinia virus DIs strain against mpox virus infection in mice

Chunlin	<b>XIN</b>	<b>P147</b>	Introduce a novel proprietary Lipid Nanoparticle (LNP)
Makutiro	<b>Masavuli</b>	<b>P148</b>	Novel multi-genotypic E2E1 nanoparticle HCV vaccines
Hyojin	<b>Kim</b>	<b>P149</b>	Targeting immunosubdominant epitopes via antigen monomerization
Liubov	<b>Kozlovskaya</b>	<b>P150</b>	A chimeric vaccine based on a fusion protein combining RBDs from Wuhan and Omicron SARS-CoV-2 variants protects against Omicron infection in Syrian hamsters
Liubov	<b>Kozlovskaya</b>	<b>P151</b>	iVDPV2: a threat for the polio-free world or not?
Yi	<b>Zhang</b>	<b>P152</b>	Pathogen distribution and pneumococcus disease burden of clinical diagnosed pneumonia among children, a multi-center case-control study
Ruchir Kumar	<b>PANSURIYA</b>	<b>P153</b>	Comprehensive Scalable Production and Analytical Characterization of O-specific Polysaccharides from Various Salmonella Enterica serovars
Seokchan	<b>PARK</b>	<b>P154</b>	Intranasal spike protein with mucosal combination adjuvant: potential for standard vaccine and heterologous boost for mRNA vaccine against SARS-CoV-2
Qiubin	<b>Lin</b>	<b>P155</b>	A Novel Outer Membrane Vesicle (OMV) Vaccine Platform for Low-Cost, Broadly Protective Vaccines: A Case Study of an MenB OMV Vaccine